Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.86M Sell
290,099
-139,181
-32% -$3.1M 0.03% 385
2025
Q4
$8.23M Sell
429,280
-3,163
-0.7% -$66.5K 0.03% 403
2025
Q3
$10.4M Buy
+432,443
New +$10.1M 0.04% 327
2022
Q3
Sell
-66,124
Closed -$1.96M 869
2022
Q2
$1.96M Sell
66,124
-2,272
-3% -$76.3K 0.01% 688
2022
Q1
$2.79M Sell
68,396
-17,214
-20% -$739K 0.01% 612
2021
Q4
$4.1M Sell
85,610
-56,958
-40% -$2.55M 0.02% 338
2021
Q3
$5.91M Buy
142,568
+50,766
+55% +$2.02M 0.03% 270
2021
Q2
$4.15M Sell
91,802
-6,894
-7% -$322K 0.03% 363
2021
Q1
$4.36M Buy
+98,696
New +$3.73M 0.04% 231
2020
Q4
Sell
-24,934
Closed -$432K 527
2020
Q3
$432K Buy
24,934
+4,695
+23% +$81.8K 0.01% 411
2020
Q2
$332K Sell
20,239
-1,378
-6% -$21K 0.01% 316
2020
Q1
$196K Sell
21,617
-10,386
-32% -$209K ﹤0.01% 381
2019
Q4
$680K Buy
+32,003
New +$710K 0.01% 379

Other funds holding ADNT

Ray Dalio's ADNT Position: Q1 2026 in Review

Ray Dalio reduced its Adient (ADNT) stake by 32% in Q1 2026, selling an estimated $3.1M and leaving 290,099 shares worth $5.86M. The position accounts for 0.03% of the portfolio, ranked #385.

Ray Dalio first reported a position in ADNT in Q4 2019 and has held it in 13 quarters since. The position peaked at $10.4M in Q3 2025. 287 funds tracked by Wall St. Rank hold ADNT as of Q1 2026.

  • Ray Dalio held 290,099 shares of Adient worth $5.86M as of Q1 2026.
  • Ray Dalio sold 139,181 Adient shares in Q1 2026, an estimated $3.1M.
  • Adient made up 0.03% of Ray Dalio's portfolio in Q1 2026, its #385 holding.
  • Ray Dalio first reported a position in Adient in Q4 2019 and has held it in 13 quarters since.
  • Ray Dalio's Adient position peaked at $10.4M in Q3 2025.
  • 287 funds tracked by Wall St. Rank held Adient as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.